Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Efficacy and Safety of add-on Alpha-lipoic Acid on Migraine Prophylaxis in Adolescent Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with 15 or more headache days per month with at least 8 days having migraine features for at least 3 months (according to the criteria of the International Classification of Headache Disorders, 3rd edition \[beta version\], or ICHD-3 beta).~* Adolescent migraineurs aged 10 to 19 years of age of either sex.~* Patients who have not taken any prophylactic treatment within the last three months before their inclusion in the study.~* Patients and/or parents have given informed written consent/assent.~Exclusion Criteria:~* Patient with headache other than migraine.~* Patients who were on corticosteroids~* Treatment with any test drugs in the preceding three months from the start of the trial.~* If there is any history of interventions or devices used for the treatment of migraine, such as transcranial magnetic stimulation and nerve blocks during the 3 months before screening.~* Any other accompanying systemic illness; abnormalities revealed on neurologic examination.~* Psychiatric disturbances, history of epilepsy , learning disabilities, head trauma or use of other drugs acting on the central nervous system, including, smoking, alcohol consumption or any illicit drug abuse

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- Flunarizine (Type: ACTIVE_COMPARATOR): flunarizine will be prescribed at a dose of 5mg once daily , orally for 12 weeks
- Alpha Lipoic Acid (Type: EXPERIMENTAL): Alpha Lipoic Acid will be prescribed at a dose of 300mg once daily,orally for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).